Novo Nordisk's (NVO) third-quarter earnings were solid enough to soothe investor jitters and turn the market's attention toward upcoming trial results for a potentially game-changing new weight-loss ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Catalent (CTLT – Research Report), Moderna (MRNA – Research ...

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

The pharmaceutical company says data on 10 deaths and more than 100 hospitalizations comes from the FDA’s adverse event reporting database for semaglutide — the key ingredient in Ozempic and Wegovy, ...

Lexaria's strategy is to continue developing and optimizing our wholly-owned DehydraTECH™ drug delivery platform for application in the GLP-1 space, positioning it as a 'must-have' technology for ...

Danish drugmaker Novo Nordisk's shares hit an over 9-month low on Thursday after surging more than 8% the previous day, as ...

Novo Nordisk reported its net profit in Q3 hit 27.3 billion Danish ... by December 6 whether to clear Novo Holdings’ ...

The contract manufacturer fell short of Wall Street’s projections for its first quarter of fiscal 2025, which ended Sept. 30, ...

Novo Nordisk reported mixed Q3 earnings, but GLP-1 drugs contributed to revenue strength. The company also adjusted its ...

Novo Nordisk A/S shares rose as surging sales of the blockbuster weight-loss treatment Wegovy reassured investors after rival ...

Catalent's revenue for fiscal first quarter ended Sept. 30 was $1.02 billion, marginally below analysts' estimates of $1.06 ...